Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

NCT06333769 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

OTHER_GOV

Sponsor class

Conditions

Mid-low Rectal Cancer

Interventions

RADIATION: Short-course Radiotherapy
DRUG: Tislelizumab
DRUG: Capecitabine
DRUG: Oxaliplatin

Sponsor

Fujian Cancer Hospital